[go: up one dir, main page]

ATE165594T1 - Triarylethylenderivate zur therapeutischen verwendung - Google Patents

Triarylethylenderivate zur therapeutischen verwendung

Info

Publication number
ATE165594T1
ATE165594T1 AT94927182T AT94927182T ATE165594T1 AT E165594 T1 ATE165594 T1 AT E165594T1 AT 94927182 T AT94927182 T AT 94927182T AT 94927182 T AT94927182 T AT 94927182T AT E165594 T1 ATE165594 T1 AT E165594T1
Authority
AT
Austria
Prior art keywords
therapeutic use
derivatives
triarylethylene
agents
triarylethylene derivatives
Prior art date
Application number
AT94927182T
Other languages
English (en)
Inventor
Donald P Matthews
Alan J Bitonti
Sickle William A Van
Donald A Kaplan
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/259,797 external-priority patent/US5525633A/en
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE165594T1 publication Critical patent/ATE165594T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94927182T 1993-09-24 1994-08-19 Triarylethylenderivate zur therapeutischen verwendung ATE165594T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12661493A 1993-09-24 1993-09-24
US08/259,797 US5525633A (en) 1993-09-24 1994-06-15 Triaryl-ethylene derivatives

Publications (1)

Publication Number Publication Date
ATE165594T1 true ATE165594T1 (de) 1998-05-15

Family

ID=26824862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927182T ATE165594T1 (de) 1993-09-24 1994-08-19 Triarylethylenderivate zur therapeutischen verwendung

Country Status (17)

Country Link
US (1) US5684004A (de)
EP (1) EP0720597B1 (de)
JP (1) JPH09503761A (de)
CN (1) CN1131415A (de)
AT (1) ATE165594T1 (de)
AU (1) AU678535B2 (de)
CA (1) CA2171728C (de)
DE (1) DE69409961T2 (de)
DK (1) DK0720597T3 (de)
ES (1) ES2115975T3 (de)
FI (1) FI961339A7 (de)
HU (1) HUT75933A (de)
IL (1) IL111018A0 (de)
NO (1) NO306292B1 (de)
NZ (1) NZ273433A (de)
PL (1) PL177833B1 (de)
WO (1) WO1995008528A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP3827747A1 (de) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharmainformatiksystem
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
PT3395372T (pt) 2009-02-20 2022-05-05 Enhanx Biopharm Inc Sistema de entrega de medicamentos à base de glutationa
KR101741629B1 (ko) 2009-05-06 2017-05-31 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten

Also Published As

Publication number Publication date
NZ273433A (en) 1997-11-24
PL313594A1 (en) 1996-07-08
FI961339A0 (fi) 1996-03-22
NO306292B1 (no) 1999-10-18
CN1131415A (zh) 1996-09-18
CA2171728C (en) 2001-11-13
NO961204L (no) 1996-03-25
NO961204D0 (no) 1996-03-25
EP0720597B1 (de) 1998-04-29
AU7670794A (en) 1995-04-10
FI961339L (fi) 1996-03-22
HU9600727D0 (en) 1996-05-28
IL111018A0 (en) 1994-11-28
US5684004A (en) 1997-11-04
JPH09503761A (ja) 1997-04-15
CA2171728A1 (en) 1995-03-30
DK0720597T3 (da) 1998-10-07
DE69409961D1 (de) 1998-06-04
ES2115975T3 (es) 1998-07-01
PL177833B1 (pl) 2000-01-31
AU678535B2 (en) 1997-05-29
FI961339A7 (fi) 1996-03-22
DE69409961T2 (de) 1998-09-10
EP0720597A1 (de) 1996-07-10
WO1995008528A1 (en) 1995-03-30
HUT75933A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ID23374A (id) Halogenopirimidin
ATE238790T1 (de) Verwendung von pramipexole als neuroschutzmittel
EA199800667A1 (ru) Новые фенантридины
DE69939864D1 (de) Ppar-gamma modulatoren
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
TR200200068T2 (tr) Nematisital triflüorobütenler
GB9406857D0 (en) Improvements in or relating to organic compounds
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
BR9711586A (pt) Compostos e uso dos mesmo
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
MY105128A (en) Bu-3608 derivatives.
BG100248A (bg) Инхибитори на скваленсинтетаза
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
BG101221A (bg) N-заместени азабициклохептанови производни, приложими като невролептици
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
ID27733A (id) Metoksiminofenilasetamida
AU6832498A (en) Substituted benzyl oximino compounds
BR9808210A (pt) Befeniloxazolinas dissubstituìdas
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee